|
BIIB | Biogen Inc. |
| Biological Products (no Diagnostic Substances) |
| Book value per $ invested | $ 2.03 |
| Leverage | 37.57% |
| Market Cap | $ 27.2B |
| PE | 19.81 |
| Dividend Yield | 0.00% |
| Profit | $ 1.4B |
| Margin | 13.88% |
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide.